Welcome to our dedicated page for Insmed news (Ticker: INSM), a resource for investors and traders seeking the latest updates and insights on Insmed stock.
News and press releases about Insmed Incorporated (INSM) provide insight into the company’s progress as a global biopharmaceutical organization focused on serious and rare diseases. Insmed regularly issues updates on its commercial performance, clinical trial milestones, regulatory decisions, and corporate initiatives across its respiratory, immunology & inflammation, and neuro & other rare disease programs.
Recent news has highlighted key events such as U.S. Food and Drug Administration approval of BRINSUPRI (brensocatib) for non-cystic fibrosis bronchiectasis, European Commission approval of BRINSUPRI for specified NCFB patients in the European Union, and detailed business updates around the commercial launch of BRINSUPRI and continued global growth of ARIKAYCE (amikacin liposome inhalation suspension). Investors can also follow announcements on the advancement of TPIP (treprostinil palmitil inhalation powder) into Phase 3 studies for pulmonary hypertension associated with interstitial lung disease and other pulmonary indications.
Insmed’s news flow also covers clinical data readouts from studies such as ASPEN and WILLOW in NCFB, the BiRCh and CEDAR trials evaluating brensocatib in additional neutrophil-mediated diseases, and early-stage developments in gene therapy programs INS1201, INS1202, and INS1203. Corporate communications include financial results, conference presentations at major healthcare and respiratory congresses, and updates on acquisitions such as INS1148, an investigational monoclonal antibody for respiratory and inflammatory conditions.
For followers of INSM stock, this news page offers a centralized view of Insmed’s ongoing commercial execution, regulatory interactions, and pipeline evolution. Regular updates help track how the company’s therapies and investigational candidates are progressing through development and reaching patient populations worldwide.
On July 8, 2022, Insmed Incorporated (Nasdaq: INSM) announced inducement awards to 18 employees, a move approved by the Compensation Committee under NASDAQ Listing Rule 5635(c)(4). These new hires received options to purchase 146,070 shares of common stock at $20.89 each, the closing price on July 1, 2022. The options have a 10-year term with a four-year vesting schedule, promoting employee retention. Insmed, based in Bridgewater, New Jersey, focuses on therapies for serious and rare diseases and has a growing pipeline of investigational treatments.
Insmed Incorporated (Nasdaq: INSM) announced that it has granted inducement awards to 24 new employees as part of their employment offer. The approved awards, compliant with NASDAQ Listing Rule 5635(c)(4), include options to purchase 158,530 shares of common stock at an exercise price of $17.93 per share, equivalent to the closing price on June 1, 2022. The options have a 10-year term and a four-year vesting schedule. Insmed is focused on therapies for serious and rare diseases, with a strong commitment to enhancing patient lives.
Insmed has appointed Drayton Wise as the new Chief Commercial Officer, effective May 23, 2022. He will lead global commercial functions and continue overseeing the ARIKAYCE franchise. This strategic move comes as Insmed prepares for significant milestones, including expanding ARIKAYCE's market reach and launching new products like brensocatib. Drayton has been pivotal in building Insmed's commercial organization since joining in 2014. Will Lewis, CEO, expressed confidence in Wise's leadership during this critical phase.
Insmed Incorporated (Nasdaq: INSM) presented new findings at the ATS 2022 International Conference, showcasing significant benefits of ARIKAYCE and brensocatib. A retrospective study revealed a reduction in all-cause hospitalizations from 35.9% to 23.0% in patients following ARIKAYCE treatment, with similar improvements in respiratory-related hospitalizations. Additionally, post-hoc analyses of the WILLOW study indicated a favorable benefit-risk profile for brensocatib, noting a low number needed to treat (NNT) of 6-7 and a negative number needed to harm (NNH), suggesting a lower risk of severe adverse events compared to placebo.
Insmed Incorporated (Nasdaq: INSM), a biopharmaceutical company focused on rare diseases, will present in a fireside chat at the H.C. Wainwright Annual Global Life Sciences Conference. The event is scheduled for on-demand viewing on May 24, 2022, at 7:00 a.m. ET, accessible through the company's investor relations site. Insmed is known for its first-in-disease therapy for chronic lung disease and has a pipeline aimed at unmet medical needs in inflammatory and pulmonary disorders. The webcast will be available for 30 days post-presentation.
On May 6, 2022, Insmed Incorporated (Nasdaq: INSM) announced the granting of inducement awards to 10 new employees as per NASDAQ Listing Rule 5635(c)(4). These awards include options to purchase 70,080 shares of common stock at $22.45 per share, the closing price on May 2, 2022. The options have a 10-year term with a four-year vesting schedule. Insmed is focused on transforming the lives of patients with serious and rare diseases, with its first commercial product approved in the U.S., Europe, and Japan.
Insmed Incorporated (Nasdaq:INSM) reported strong Q1 2022 results, achieving 32% year-over-year growth with total revenue of $53.1 million, driven by ARIKAYCE sales of $40.8 million in the U.S. The company maintains its 2022 revenue guidance of at least 30% growth and a cash runway into 2024. Seven clinical trials are ongoing, including the Phase 3 ASPEN study for brensocatib. Despite a net loss of $94.6 million for the quarter, Insmed's financial position remains strong as it continues to invest in expansion and research initiatives.
Insmed, a biopharmaceutical company focused on rare diseases, plans to release its Q1 2022 financial results on May 5, 2022. The management will conduct a conference call at 8:30 a.m. ET on the same day to discuss the results and provide a business update. Interested parties can join the call via phone or through a live webcast on the company's website. Insmed aims to transform lives with innovative therapies and is progressing in various serious unmet medical needs.
Insmed Incorporated (Nasdaq: INSM) announced on April 7, 2022, the granting of inducement awards to 20 new employees as part of NASDAQ Listing Rule 5635(c)(4). Each employee received options to purchase a total of 107,680 shares at an exercise price of $24.47 per share, which was the closing price on April 1, 2022. The options come with a 10-year term and a four-year vesting schedule. Insmed focuses on developing therapies for serious and rare diseases, with its first product approved in the US, Europe, and Japan.
Insmed (Nasdaq: INSM) will present seven posters at the ATS 2022 International Conference, highlighting data on ARIKAYCE, brensocatib, and treprostinil palmitil inhalation powder. Key presentations include real-world evidence on ARIKAYCE's effectiveness in reducing hospitalizations and an analysis of the benefit-risk profile of brensocatib in bronchiectasis patients. The conference, set for May 13-18, 2022, in San Francisco, is a platform for the latest advancements in treatments for serious diseases.